CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity

Area of Science:

• Pharmacology
• Neuroscience
• Cardiovascular Research

Background:

• Adenosine receptors play crucial roles in various physiological processes.
• Selective ligands for adenosine receptor subtypes are valuable research tools.

Purpose of the Study:

• To characterize the in vitro and in vivo pharmacological profiles of novel adenosine analogs, CGS 21680C and CGS 21577.
• To evaluate their selectivity for adenosine A2 receptors compared to A1 receptors and other neurotransmitter sites.

Main Methods:

• In vitro radioligand binding assays to determine affinities (IC50) for adenosine A1 and A2 receptors.
• Assessment of selectivity against 17 other neurotransmitter/neuromodulator binding sites.
• In vivo studies using an isolated perfused working rat heart model to measure coronary flow and bradycardia (ED25 and EC25 values).

Main Results:

• CGS 21680C and CGS 21577 exhibited high in vitro affinity for brain striatal adenosine A2 receptors (IC50 = 22 and 13 nM, respectively).
• Both compounds demonstrated significant selectivity for A2 over A1 receptors (140-fold for CGS 21680C, 59-fold for CGS 21577), outperforming the reference ligand CV 1808 (8-fold selectivity).
• CGS 21680C and CGS 21577 dose-dependently increased coronary flow in the rat heart model (ED25 = 1.8 and 3 nM, respectively) with no significant bradycardia effects at high concentrations.

Conclusions:

• CGS 21680C and CGS 21577 are highly selective adenosine A2 receptor ligands with promising cardiovascular effects.
• Their selectivity and efficacy suggest potential therapeutic applications in conditions involving adenosine A2 receptor modulation.